SPARC Q2: CONS NET LOSS NARROWS 67.8% TO ₹24.39 CR (YOY), WIDENS 17.4% (QOQ)

Revenue up 282% at ₹30.03 Cr (YOY), down 24.8% (QOQ). EBITDA loss narrowed to ₹21.99 Cr (YOY) from ₹65.71 Cr; worsened from ₹10.34 Cr (QOQ). Caution: Prior-year other operating revenue included ₹1,840.02 Cr PRV income; PRV sold for USD 195 MN, current quarter has no such item.

Sun Pharma Advanced Research Company Limited

Open attachment

← Back to feed